Figure 5.

IGF2-AS inhibits tumor growth in vivo. (a, b) The volume and weight of tumor of nude mice in control and IGF2-AS-overexpressing groups (n = 6 in each group). (c, d) IHC staining of Ki-67, IGF2, and p-AKT in control and IGF2-AS-overexpressing tumor tissues. Scale bar = 20 µM. (e) The proposed model showing the tumor-inhibiting role of IGF2-AS in breast cancer by acting as DNMT1 protein binding partner and dampening oncogenic IGF2/PI3K/AKT/mTOR signaling. **P < 0.01, ***P < 0.001. (A color version of this figure is available in the online journal.)